Wednesday 6-18-2014 Albany Molecular Research (AMR
Post# of 18
Posted On: 06/18/2014 8:50:34 PM
Wednesday 6-18-2014 Albany Molecular Research (AMRI) $AMRI opened at 19.49 hitting the high price of 20.05 and a day low of 19.39 with a total volume of 916,084. AMRI had a previous close of 19.41 and has been seeing an average volume of 418,295.
Overall Average: 96% Buy
Recent stock forum discussions about AMRI http://investorshangout.com/search?q=AMRI&...mp;yt0=Go!
Uptrend Call Working As Albany Molecular Research Stock Rises 15.6% (AMRI)
Comtex SmarTrend(R) - Wed Jun 18, 9:31AM CDT
SmarTrend identified an Uptrend for Albany Molecular Research (NASDAQ:AMRI) on June 3rd, 2014 at $17.04. In approximately 2 weeks, Albany Molecular Research has returned 15.61% as of today's recent price of $19.70. (full story)
Using the Short Ratio to Forecast Turning Points - Screen of the Week
Kevin Matras - ZACKS - Tue Jun 17, 2:57AM CDT
Using the Short Ratio to Forecast Turning Points - Screen of the Week (full story)
3 Stocks Spiking on Big Volume
at The Street - Thu Jun 12, 8:17AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility. (full story)
AMRI CEO to Present at the 2014 Wells Fargo Healthcare Conference
PR Newswire Europe - Wed Jun 11, 5:55AM CDT
Albany Molecular Research Inc. announced today that William S. Marth, President and Chief Executive Officer at AMRI, will present at the 2014 Wells Fargo Healthcare Conference on Tuesday, June 17, 2014 at 10:00 a.m. ET. (full story)
AMRI to Acquire Oso Biopharmaceuticals Manufacturing
PR Newswire Europe - Wed Jun 11, 5:29AM CDT
- Significantly Expands Contract Manufacturing Capabilities to Include Commercial Scale Sterile Injectables - (full story)
AMRI CEO to Present at the Jefferies 2014 Global Healthcare Conference
PR Newswire Europe - Wed Jun 11, 12:29AM CDT
Albany Molecular Research Inc. announced today that William S. Marth, President and Chief Executive Officer at AMRI, will present at the Jefferies 2014 Global Healthcare Conference on Monday, June 2, 2014 at 3:30 p.m. ET. (full story)
Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 6th Edition
M2 - Mon Jun 09, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k9zb74/outsourcing_in) has announced the addition of the "Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 6th Edition" report to their offering. For six editions, this authoritative resource has defined the market opportunity for companies assisting in the beginning phase of the drug development process. This Kalorama Information Report, Outsourcing in Drug Discovery, t provides an in depth look into the trends that have shaped the drug discovery outsourcing market today, and details the current and future global market. As part of its coverage, the report provides markets and forecasts for the following segments. The following companies are profiled in the report: Albany Molecular Research, Inc. Aptuit, LLC Argenta Discovery, Ltd. Asclepia MedChem Solutions Asinex Ltd. AsisChem, Inc. Axxam SpA BioDuro BioFocus DPI Caliper Life Sciences Charles River Laboratories, Inc. ChemBridge Corp. Chemical Diversity Inc. Covance, Inc. CreaGen Biosciences, Inc. Crown Bioscience Cyprotex PLC Domainex Emerald Biostructures Enamine Ltd. Evotec AG Exelgen Discovery GVK Biosciences Private Limited GenScript USA Inc. Graffinity Pharmaceuticals GmbH Hutchison MediPharma Ltd. Jubilant Biosys Ltd Nanosyn, Inc. Pharmaron Inc. Ricerca Biosciences, LLC Scynexis, Inc. Selcia Limited Selvita S.A. Shanghai ChemPartner Co., Ltd. Shanghai Medicilon Inc. Sundia Meditech Company, Ltd. Sygnature Discovery Limited TCG Lifesciences Limited Viva Biotech, Ltd WuXI AppTec Co. Ltd. Key Topics Covered: ONE: EXECUTIVE SUMMARY TWO: INTRODUCTION TO OUTSOURCING DRUG DISCOVERY THREE: THE DRUG DISCOVERY PROCESS FOUR: OUTSOURCING DRUG DISCOVERY FIVE: DRUG DISCOVERY OUTSOURCING MARKET SIX: COMPETITOR PROFILES For more information visit http://www.researchandmarkets.com/research/k9...ourcing_in (full story)
Clinical Study Results, Data Presentations, DMF Submissions, and Acquisition Agreements - Analyst Notes on Forest Laboratories, Incyte, Illumina, INSYS Therapeutics and AMRI
PR Newswire - Thu Jun 05, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Forest Laboratories Inc. (NYSE: FRX), Incyte Corporation (NASDAQ: INCY), Illumina Inc. (NASDAQ: ILMN), INSYS Therapeutics, Inc. (NASDAQ: INSY) and Albany Molecular Research Inc. (NASDAQ: AMRI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3391-100free. (full story)
Global Antibody Drug Conjugates Contract Manufacturing Market Report 2013-2018 & 2019-2024
M2 - Wed May 21, 3:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v8wjtr/antibody_drug) has announced the addition of the "Global Antibody Drug Conjugates Contract Manufacturing Market Report 2013-2018 & 2019-2024" report to their offering. The report provides short-mid term and long term market forecasts for the period 2013 - 2018 and 2019 - 2024, respectively. We have discussed, in detail, the key drivers behind the growth of this market. The estimated sales figures of the ADC therapeutics market forms the basis for our analysis of the forecasted revenues for CMOs. Any changes in the ADC market and its growth are likely to alter the outsourcing activity in the market. One of the key objectives of this report is to understand the current state and future potential for CMOs in the market. This is done by analysing: - The rich pipeline of ADC therapeutics - Commercial sales potential for various ADC molecules under development - Likely outsourcing profile across various steps involved in ADC manufacturing - In-house / contract manufacturing status of various components of phase II, phase III and marketed ADCs Summary of Report Highlights - Only a few ADC developers have in-house manufacturing facilities; majority of the companies, including the leading technology providers (Seattle Genetics and ImmunoGen) are dependent on contract manufacturers to supply the components. - Discussions with senior experts in the industry reveal that around 70%-80% of ADC manufacturing is outsourced. - Manufacturing of ADCs poses significant challenges due to nature of these molecules. Managing the supply chain and working with multiple CMOs adds to the complexity of the manufacturing process; one-stop-shops are rarity in this field. - The overall market for contract manufacturing of ADCs is likely to exceed the 1 billion dollar mark in the coming decade; the presence of both large and small biotech companies is funding the growing pipeline of ADCs. - Numerous partnership opportunities exist for CMOs to bring together their complementary skills; such partnerships will enable further advancements in this field without significantly enhancing the capital exposure. Key Topics Covered: 1. Prelude 2. Executive Summary 3. Introduction 4. ADC Therapeutics: Development Overview 5. Manufacturing Of ADCS: A Market Overview 6. CMOS: Worldwide Landscape 7. Profiles Of Leading Companies 8. Market Size And Forecast 9. Swot Analysis 10. Interview Transcripts 11. Conclusion 12. List Of Companies And Organisations 13. Tables Leading Companies: - Lonza - Piramal Healthcare Pharma Solutions - Albany Molecular Research (AMRI Global) - BSP Pharmaceuticals - Pierre Fabre Laboratories - Catalent Pharma Solutions For more information visit http://www.researchandmarkets.com/research/v8...ibody_drug (full story)
Insider Trading Alert - AMRI, ULTI And MHFI Traded By Insiders
at The Street - Wed May 14, 12:30PM CDT
Stocks with insider trader activity include AMRI, ULTI and MHFI (full story)
Health Care Sector Equities Technical Data -- Research on Albany Molecular Research, Agilent Technologies, Thermo Fisher Scientific, and ICON
PR Newswire - Tue May 13, 8:15AM CDT
The U.S. markets on Monday, May 12, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,695.47, up 0.68% and the NASDAQ Composite closed at 4,143.86, up 1.77%. The S&P 500 finished the session 0.97% higher at 1,896.65. During the trading session, eight out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 675.29, up 1.04%, with the index advancing 4.74% in the last one month. Investor-Edge has initiated coverage on the following equities: Albany Molecular Research Inc. (NASDAQ: AMRI), Agilent Technologies Inc. (NYSE: A), Thermo Fisher Scientific Inc. (NYSE: TMO) and ICON PLC (NASDAQ: ICLR). Free technical research on AMRI, A, TMO and ICLR can be downloaded upon signing up at: (full story)
AMRI CEO to Present at the UBS Global Healthcare Conference
PR Newswire Europe - Thu May 08, 4:54AM CDT
Albany Molecular Research Inc. announced today that William S. Marth, President and Chief Executive Officer at AMRI, will present at the UBS Global Healthcare Conference on Wednesday, May 21, 2014 at 11:00 a.m. ET. (full story)
Insider Trading Alert - AMRI, STT And MLNX Traded By Insiders
at The Street - Tue May 06, 12:45PM CDT
Stocks with insider trader activity include AMRI, STT and MLNX (full story)
AMRI Announces First Quarter 2014 Results
PR Newswire Europe - Tue May 06, 7:02AM CDT
-- Contract Revenue Growth of 10% to $51.0 Million and Adjusted Diluted EPS of $0.16 (full story)
Overall Average: 96% Buy
Recent stock forum discussions about AMRI http://investorshangout.com/search?q=AMRI&...mp;yt0=Go!
Uptrend Call Working As Albany Molecular Research Stock Rises 15.6% (AMRI)
Comtex SmarTrend(R) - Wed Jun 18, 9:31AM CDT
SmarTrend identified an Uptrend for Albany Molecular Research (NASDAQ:AMRI) on June 3rd, 2014 at $17.04. In approximately 2 weeks, Albany Molecular Research has returned 15.61% as of today's recent price of $19.70. (full story)
Using the Short Ratio to Forecast Turning Points - Screen of the Week
Kevin Matras - ZACKS - Tue Jun 17, 2:57AM CDT
Using the Short Ratio to Forecast Turning Points - Screen of the Week (full story)
3 Stocks Spiking on Big Volume
at The Street - Thu Jun 12, 8:17AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility. (full story)
AMRI CEO to Present at the 2014 Wells Fargo Healthcare Conference
PR Newswire Europe - Wed Jun 11, 5:55AM CDT
Albany Molecular Research Inc. announced today that William S. Marth, President and Chief Executive Officer at AMRI, will present at the 2014 Wells Fargo Healthcare Conference on Tuesday, June 17, 2014 at 10:00 a.m. ET. (full story)
AMRI to Acquire Oso Biopharmaceuticals Manufacturing
PR Newswire Europe - Wed Jun 11, 5:29AM CDT
- Significantly Expands Contract Manufacturing Capabilities to Include Commercial Scale Sterile Injectables - (full story)
AMRI CEO to Present at the Jefferies 2014 Global Healthcare Conference
PR Newswire Europe - Wed Jun 11, 12:29AM CDT
Albany Molecular Research Inc. announced today that William S. Marth, President and Chief Executive Officer at AMRI, will present at the Jefferies 2014 Global Healthcare Conference on Monday, June 2, 2014 at 3:30 p.m. ET. (full story)
Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 6th Edition
M2 - Mon Jun 09, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k9zb74/outsourcing_in) has announced the addition of the "Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 6th Edition" report to their offering. For six editions, this authoritative resource has defined the market opportunity for companies assisting in the beginning phase of the drug development process. This Kalorama Information Report, Outsourcing in Drug Discovery, t provides an in depth look into the trends that have shaped the drug discovery outsourcing market today, and details the current and future global market. As part of its coverage, the report provides markets and forecasts for the following segments. The following companies are profiled in the report: Albany Molecular Research, Inc. Aptuit, LLC Argenta Discovery, Ltd. Asclepia MedChem Solutions Asinex Ltd. AsisChem, Inc. Axxam SpA BioDuro BioFocus DPI Caliper Life Sciences Charles River Laboratories, Inc. ChemBridge Corp. Chemical Diversity Inc. Covance, Inc. CreaGen Biosciences, Inc. Crown Bioscience Cyprotex PLC Domainex Emerald Biostructures Enamine Ltd. Evotec AG Exelgen Discovery GVK Biosciences Private Limited GenScript USA Inc. Graffinity Pharmaceuticals GmbH Hutchison MediPharma Ltd. Jubilant Biosys Ltd Nanosyn, Inc. Pharmaron Inc. Ricerca Biosciences, LLC Scynexis, Inc. Selcia Limited Selvita S.A. Shanghai ChemPartner Co., Ltd. Shanghai Medicilon Inc. Sundia Meditech Company, Ltd. Sygnature Discovery Limited TCG Lifesciences Limited Viva Biotech, Ltd WuXI AppTec Co. Ltd. Key Topics Covered: ONE: EXECUTIVE SUMMARY TWO: INTRODUCTION TO OUTSOURCING DRUG DISCOVERY THREE: THE DRUG DISCOVERY PROCESS FOUR: OUTSOURCING DRUG DISCOVERY FIVE: DRUG DISCOVERY OUTSOURCING MARKET SIX: COMPETITOR PROFILES For more information visit http://www.researchandmarkets.com/research/k9...ourcing_in (full story)
Clinical Study Results, Data Presentations, DMF Submissions, and Acquisition Agreements - Analyst Notes on Forest Laboratories, Incyte, Illumina, INSYS Therapeutics and AMRI
PR Newswire - Thu Jun 05, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Forest Laboratories Inc. (NYSE: FRX), Incyte Corporation (NASDAQ: INCY), Illumina Inc. (NASDAQ: ILMN), INSYS Therapeutics, Inc. (NASDAQ: INSY) and Albany Molecular Research Inc. (NASDAQ: AMRI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3391-100free. (full story)
Global Antibody Drug Conjugates Contract Manufacturing Market Report 2013-2018 & 2019-2024
M2 - Wed May 21, 3:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v8wjtr/antibody_drug) has announced the addition of the "Global Antibody Drug Conjugates Contract Manufacturing Market Report 2013-2018 & 2019-2024" report to their offering. The report provides short-mid term and long term market forecasts for the period 2013 - 2018 and 2019 - 2024, respectively. We have discussed, in detail, the key drivers behind the growth of this market. The estimated sales figures of the ADC therapeutics market forms the basis for our analysis of the forecasted revenues for CMOs. Any changes in the ADC market and its growth are likely to alter the outsourcing activity in the market. One of the key objectives of this report is to understand the current state and future potential for CMOs in the market. This is done by analysing: - The rich pipeline of ADC therapeutics - Commercial sales potential for various ADC molecules under development - Likely outsourcing profile across various steps involved in ADC manufacturing - In-house / contract manufacturing status of various components of phase II, phase III and marketed ADCs Summary of Report Highlights - Only a few ADC developers have in-house manufacturing facilities; majority of the companies, including the leading technology providers (Seattle Genetics and ImmunoGen) are dependent on contract manufacturers to supply the components. - Discussions with senior experts in the industry reveal that around 70%-80% of ADC manufacturing is outsourced. - Manufacturing of ADCs poses significant challenges due to nature of these molecules. Managing the supply chain and working with multiple CMOs adds to the complexity of the manufacturing process; one-stop-shops are rarity in this field. - The overall market for contract manufacturing of ADCs is likely to exceed the 1 billion dollar mark in the coming decade; the presence of both large and small biotech companies is funding the growing pipeline of ADCs. - Numerous partnership opportunities exist for CMOs to bring together their complementary skills; such partnerships will enable further advancements in this field without significantly enhancing the capital exposure. Key Topics Covered: 1. Prelude 2. Executive Summary 3. Introduction 4. ADC Therapeutics: Development Overview 5. Manufacturing Of ADCS: A Market Overview 6. CMOS: Worldwide Landscape 7. Profiles Of Leading Companies 8. Market Size And Forecast 9. Swot Analysis 10. Interview Transcripts 11. Conclusion 12. List Of Companies And Organisations 13. Tables Leading Companies: - Lonza - Piramal Healthcare Pharma Solutions - Albany Molecular Research (AMRI Global) - BSP Pharmaceuticals - Pierre Fabre Laboratories - Catalent Pharma Solutions For more information visit http://www.researchandmarkets.com/research/v8...ibody_drug (full story)
Insider Trading Alert - AMRI, ULTI And MHFI Traded By Insiders
at The Street - Wed May 14, 12:30PM CDT
Stocks with insider trader activity include AMRI, ULTI and MHFI (full story)
Health Care Sector Equities Technical Data -- Research on Albany Molecular Research, Agilent Technologies, Thermo Fisher Scientific, and ICON
PR Newswire - Tue May 13, 8:15AM CDT
The U.S. markets on Monday, May 12, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,695.47, up 0.68% and the NASDAQ Composite closed at 4,143.86, up 1.77%. The S&P 500 finished the session 0.97% higher at 1,896.65. During the trading session, eight out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 675.29, up 1.04%, with the index advancing 4.74% in the last one month. Investor-Edge has initiated coverage on the following equities: Albany Molecular Research Inc. (NASDAQ: AMRI), Agilent Technologies Inc. (NYSE: A), Thermo Fisher Scientific Inc. (NYSE: TMO) and ICON PLC (NASDAQ: ICLR). Free technical research on AMRI, A, TMO and ICLR can be downloaded upon signing up at: (full story)
AMRI CEO to Present at the UBS Global Healthcare Conference
PR Newswire Europe - Thu May 08, 4:54AM CDT
Albany Molecular Research Inc. announced today that William S. Marth, President and Chief Executive Officer at AMRI, will present at the UBS Global Healthcare Conference on Wednesday, May 21, 2014 at 11:00 a.m. ET. (full story)
Insider Trading Alert - AMRI, STT And MLNX Traded By Insiders
at The Street - Tue May 06, 12:45PM CDT
Stocks with insider trader activity include AMRI, STT and MLNX (full story)
AMRI Announces First Quarter 2014 Results
PR Newswire Europe - Tue May 06, 7:02AM CDT
-- Contract Revenue Growth of 10% to $51.0 Million and Adjusted Diluted EPS of $0.16 (full story)
(0)
(0)Albany Molecular Research (AMRI) Stock Research Links
Scroll down for more posts ▼